2020
Evaluation of stroke incidence with duty‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study
Hummel J, Verma A, Calkins H, Schwamm L, Gress D, Wells D, Souza J, Hokanson R, Hemingway L, Stromberg K, Hoyt R, Wickliffe A, DeLurgio D, Boersma L. Evaluation of stroke incidence with duty‐cycled multielectrode‐phased radiofrequency ablation of persistent atrial fibrillation results of the VICTORY AF Study. Journal Of Cardiovascular Electrophysiology 2020, 31: 1289-1297. PMID: 32270538, DOI: 10.1111/jce.14483.Peer-Reviewed Original ResearchConceptsDevice-related strokesAcute procedural successAtrial fibrillationAF trialSecondary outcomesStroke incidenceProcedural successAF studyStroke/transient ischemic attackVitamin K antagonist anticoagulationMajor structural heart diseasePulmonary vein stenosisTransient ischemic attackIncidence of strokeStructural heart diseaseNumber of patientsVitamin K antagonismAtrial fibrillation resultsRigorous clinical evaluationIDE trialIschemic attackNeurologist assessmentPersAF patientsAF burdenPV stenosis
2016
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL
Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation Arrhythmia And Electrophysiology 2016, 9 PMID: 27307517, PMCID: PMC4911813, DOI: 10.1161/circep.115.003407.Peer-Reviewed Original ResearchConceptsLAA closureLeft atrial appendageQuality-adjusted life yearsPROTECT AFAtrial fibrillationPercutaneous closureWatchman deviceAtrial appendageLife yearsTrial dataWATCHMAN LAA closure devicePROTECT AF trialIncremental cost-effectiveness ratioMajor adverse eventsPrevention of strokeAtrial appendage closureProspective Randomized EvaluationLAA closure deviceLong-term trial resultsQuality-adjusted survivalCost-effectiveness ratioCost-effectiveness resultsMedical anticoagulationAF trialAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply